All articles by Phalguni Deswal
Phalguni Deswal is a trainee healthcare reporter for Clinical Trials Arena. With a background in medicine, Phalguni has experience working in the Indian healthcare sector. Phalguni is interested in metabolic drug therapies, digital health technologies, and drug development.
Phalguni Deswal
Bluejay Therapeutics makes progress in Hepatitis B and D Trials
Bluejay Therapeutics reported completion of Phase Ia trial for its monoclonal antibody for Hepatitis B and D.
AstraZeneca abandons inflammatory bowel disease drug
The British drugmaker has discontinued its monoclonal antibody inflammatory bowel disease (IBD) development programme citing trial delays.
Hookipa debuts Phase I/II data
The company released Phase I/II clinical and safety data plus trial update for single and combination therapy for patients with HPV16+ head and neck cancer.
NeuroMetrix encouraged by Phase II Quell data
NeuroMetrix reported trial data for its wireless transcutaneous electric nerve stimulation device for chemotherapy-induced peripheral neuropathy.
Pfizer’s haemophilia drug succeeds in Phase III trial
The company’s Phase III trial results showed reduced bleeding events for once-a-week antibody treatment for haemophilia A and B.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Positive Phase I results for Prader-Willi Syndrome drug
ConSynance’s novel therapy for the rare central nervous system disorder is looking to advance to Phase II trials in view of positive findings.
Cora highlights data for DNA protecting supplement
Cora Therapeutics reported results from a new trial assessing Halo in safeguarding DNA from X-ray radiation exposure.
Merck and Eisai tease results for renal carcinoma treatment
The companies are reporting better results for their combination therapy than the current treatment for advanced renal cell carcinoma.
Antabio on quest to tackle antibiotic resistance
The Phase I trial for ventilator-associated pneumonia combination antibiotic has dosed its first subject.
Transgene and BioInvent report positive data for oncolytic virus
BioInvent and Transgene’s oncolytic virus BT-001 is now ready for a combination therapy trial.